
PanGen under Huons continues solid growth with EPO biosimilar and CDMO biz
PanGen Biotech, a biopharmaceutical affiliate under Huons Group, is maintaining its growth trajectory this year after achieving profitability in 2024. The company said it plans to accelerate earnings expansion by leveraging its biosimilar portfolio and …